Amgen-AstraZeneca Imdelltra plus Imfinzi improves survival in SCLC trial
Amgen said its Imdelltra targeted immunotherapy with AstraZeneca’s Imfinzi significantly improved overall survival in extensive-stage small-cell lung cancer in a late-stage trial, the companies said on Tuesday.
Amgen’s targeted immunotherapy Imdelltra, used with AstraZeneca’s cancer drug Imfinzi, significantly improved overall survival in patients with extensive-stage small-cell lung cancer in a late-stage trial, the companies said on Tuesday.